China-Singapore Jingwei, January 11 According to the State Drug Administration, from January 9 to 10, the National Drug Administration Work Conference was held in Beijing.
The meeting made specific arrangements for drug supervision in 2024 in four aspects. The first is to take the initiative to prevent and control drug safety risks. Take the prevention and resolution of drug quality and safety risks as the fundamental task of drug supervision, play a good "first move" in risk forward-looking prevention and control, continue to deepen the consolidation and improvement of drug safety, do a good job in the supervision of key varieties, key enterprises and key links, and promote the linkage of the supervision responsibility of the drug safety department, the responsibility of territorial management and the main responsibility of the enterprise, and effectively resolve the risk in the bud.
The second is to create an efficient and fair regulatory environment. Give full play to the role of supervision and guidance, deepen the reform of the review and approval system, actively support pharmaceutical R&D and innovation, promote the inheritance, innovation and development of traditional Chinese medicine, continue to improve the level of convenience for enterprises and people, and promote the construction of an industrial ecology that supports the virtuous cycle of R&D, production, sales and clinical application of innovative drugs and devices.
The third is to accelerate the pace of modernization of drug supervision. Strengthen institutional innovation and means innovation, strengthen the construction of the rule of law in drug supervision, continuously improve the level of regulatory informatization, deepen regulatory scientific research and international cooperation, build a team of high-quality professional cadres and talents, and accelerate the improvement of drug regulatory efficiency.
Fourth, we should promote the comprehensive and strict governance of the party to develop in depth. We will continue to improve the comprehensive efficacy of the "three non-corruptions", strengthen the spiritual forging and ability tempering of the drug regulatory cadre team, and lead the high-quality development of the drug regulatory industry with high-quality party building. (Zhongxin Jingwei app).
For more exciting content, please pay attention to the official WeChat of JWVIEW***